Abbott Laboratories

• 8-KNegativeImpairment / chargeLegal / investigation

  Filed Aug 20

  Preterm infant formula settlements resolve Gill and additional claims after the verdict was upheld on appeal; other lawsuits remain pending.

• 10-QQ2 FY2026

  Filed Jul 28

  Exact Sciences lifts cancer-diagnostics sales, but financing, amortization, integration costs and legal reserves outweigh segment earnings gains.

  • Revenue$12.6BYoY +13.0%
  • Net income$928.0MYoY −47.8%

• 8-KPositiveEarningsGuidance raisedImpairment / chargeLegal / investigation

  Filed Jul 16

  Exact Sciences acquisition boosted reported Diagnostics growth; Abbott raised its FY2026 adjusted EPS outlook.

Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.

Request longer coverage

Company data: Wikidata Q306764